Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]
News [7838]
Articles [63]
Editorials [9]
Conferences [210]
elearning [49]
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
ZUMA-7: Axi-cel is superior to standard of care across common prognostic...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...
Dr Ian Krop - Yale Cancer Center, Connecticut, USA
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )
23 Dec 2022
ASH 2022: Multiple myeloma roundup
Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...
Dr Monzr Al Malki - City of Hope, Duarte, USA
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease  ( Dr Monzr Al Malki - City of Hope, Duarte, USA )
21 Dec 2022
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...
Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )
20 Dec 2022
Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...
Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA
Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )
19 Dec 2022
A genomic assay may predict long-term prognosis in premenopausal patients with...
Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022
Opinion: Premature regulatory approval by the FDA
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Opinion: Premature regulatory approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
13 Dec 2022
The future of precision oncology
Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany
The future of precision oncology ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )
7 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation